Hubei Key Laboratory of Tumor Biological Behaviors, Department of Radiation Oncology and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Cancer Clinical Study Center, Wuhan, China.
Department of Oncology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China.
Cancer Immunol Immunother. 2024 Apr 2;73(5):94. doi: 10.1007/s00262-024-03665-x.
The advent of tumor immunotherapy in patients has revolutionized the treatment of tumors and significantly improved survival rates for a wide range of tumors. However, the full therapeutic potential of immune checkpoint inhibitors (ICIs) has yet to be realized, as not all patients have a lasting survival benefit from them, and a significant proportion of patients show primary or acquired resistance to immunotherapy. Bifidobacterium is one of the most common probiotics, and its antitumor and immunomodulatory effects have been demonstrated in recent years, but its immunomodulatory effects in tumors, especially on ICIs and in combination, have not been extensively studied in clinical practice, and its effects on the immune system and the mechanisms that modulate immunotherapy are largely unknown. Therefore, this review will focus on the immunomodulatory effects of Bifidobacteria in malignancies and the possible mechanisms of action of Bifidobacteria on immunotherapy in the hope of providing a basis for further research and better application of Bifidobacteria in clinical practice.
肿瘤免疫疗法的出现彻底改变了肿瘤的治疗方式，显著提高了多种肿瘤的生存率。然而，免疫检查点抑制剂（ICIs）的全部治疗潜力尚未得到充分发挥，因为并非所有患者都能从免疫治疗中获得持久的生存获益，而且相当一部分患者对免疫治疗表现出原发或获得性耐药。双歧杆菌是最常见的益生菌之一，近年来其抗肿瘤和免疫调节作用已得到证实，但在临床实践中，双歧杆菌在肿瘤中的免疫调节作用，特别是与 ICIs 联合使用的作用，尚未得到广泛研究，其对免疫系统的影响以及调节免疫治疗的机制在很大程度上仍是未知的。因此，本综述将重点讨论双歧杆菌在恶性肿瘤中的免疫调节作用以及双歧杆菌对免疫治疗的可能作用机制，以期为进一步研究和更好地将双歧杆菌应用于临床实践提供依据。
